Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business ...

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as ...

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury ...